Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07221357 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

A Phase 2 study of Untreated, Unresectable, or Metastatic Colorectal Cancer, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 2
Development phase
990
Enrollment target
20
Study locations

NCT07221357: Recruiting Phase 2 study of Untreated, Unresectable, or Metastatic Colorectal Cancer, sponsored by Bristol-Myers Squibb.

NCT07221357 is a Phase 2 study of Untreated, Unresectable, or Metastatic Colorectal Cancer that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 990 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (644% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07221357, a Phase 2 study of Untreated, Unresectable, or Metastatic Colorectal Cancer, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 2
Development phase
990 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic colorectal cancer

Primary Outcome

Phase 2

Conditions Studied

Untreated, Unresectable, or Metastatic Colorectal Cancer

Interventions

  • DRUG Bevacizumab
  • DRUG Pumitamig
  • DRUG FOLFIRI
  • DRUG FOLFOX
  • DRUG CAPOX

Study Locations (20)

California

  • Local Institution - 0263 - Los Angeles
  • Local Institution - 0345 - Orange
  • Local Institution - 0317 - San Francisco
  • Local Institution - 0330 - Santa Monica
  • Local Institution - 0293 - Stanford

Florida

  • Florida Cancer Specialists - East - Cape Coral
  • Florida Cancer Specialists - North - St. Petersburg
  • Local Institution - 0269 - Tampa

Georgia

  • Local Institution - 0276 - Duluth
  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital - Marietta

Illinois

  • Local Institution - 0030 - Chicago
  • Local Institution - 0433 - Chicago

Maryland

  • Local Institution - 0262 - Baltimore
  • Maryland Oncology Hematology - Silver Spring - Silver Spring

Michigan

  • Local Institution - 0430 - Ann Arbor
  • Local Institution - 0254 - Grand Rapids

Arkansas

  • Local Institution - 0432 - Springdale

Iowa

  • Local Institution - 0335 - Iowa City

Trial Details

FieldValue
Enrollment Target 990 participants
Start Date 2025-12-31
Est. Completion 2034-03-11
Phase Phase 2
Bristol-Myers Squibb

1,025 total trials

What NCT07221357 shows while recruiting

NCT07221357 is an interventional study that assigns participants to a tested intervention. The registered 990 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (644% higher).

The record links to 1 condition, with Untreated, Unresectable, or Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.

NCT07221357 names 20 study sites across 10 states, led by California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT07221357 about?

NCT07221357 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer". The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic colorectal cancer

What is the current status of trial NCT07221357?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 990 participants. The study started on 2025-12-31. Estimated completion is 2034-03-11.

What conditions does trial NCT07221357 study?

This clinical trial studies the following conditions: Untreated, Unresectable, or Metastatic Colorectal Cancer.

What interventions are being tested in trial NCT07221357?

The interventions under investigation include: Bevacizumab (DRUG), Pumitamig (DRUG), FOLFIRI (DRUG), FOLFOX (DRUG), CAPOX (DRUG).

Who is sponsoring clinical trial NCT07221357?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07221357 being conducted?

This trial has 20 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT07221357's enrollment target sits among peer trials

990 27th of 2000 higher than 1,974 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05441709 · 990 participants · NA

    Furthering Equity Through Infant Feeding EDucation and Support

  • NCT06340646 · 990 participants · NA

    Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

  • NCT06878261 · 990 participants · Phase 3

    A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

  • NCT06883305 · 990 participants · Phase 3

    A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07221357

Source: ClinicalTrials.gov NCT07221357, the US trial registry maintained by the National Library of Medicine. NCT07221357 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.